AU448564B2 - Preparation of styryl benzylamines and phenethynyl benzylamines - Google Patents

Preparation of styryl benzylamines and phenethynyl benzylamines

Info

Publication number
AU448564B2
AU448564B2 AU20240/70A AU2024070A AU448564B2 AU 448564 B2 AU448564 B2 AU 448564B2 AU 20240/70 A AU20240/70 A AU 20240/70A AU 2024070 A AU2024070 A AU 2024070A AU 448564 B2 AU448564 B2 AU 448564B2
Authority
AU
Australia
Prior art keywords
compound
benzylamine
formula
accordance
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU20240/70A
Other versions
AU2024070A (en
Inventor
Carroll Remy David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of AU2024070A publication Critical patent/AU2024070A/en
Publication of AU448564B2 publication Critical patent/AU448564B2/en
Expired legal-status Critical Current

Links

Description

20.2 40 no
This invention relates to unsaturated derivatives of aralkylamine compounds. More specifically, it relates to substituted and
unsubstituted derivatives of styrylaralkylamines,
phenylethynylaralkylamines and the corresponding
N-substituted derivatives such as the N-alkyl and
N,N-dialkyl derivatives thereof.
This invention also relates to the novel processes and the novel intermediates utilized in the production of new aralkylamines, to pharma
ceutical formulations of the new aralkylamines and
to methods of treating or preventing cardiac
arrhythmias using the novel compounds and/or pharma-
ceutical formulations thereof, described hereinafter.
A preferrodcl-ase-of-compounds of my invention are represented structurally as aralkyl-
amines of the formula:
4 48.5 6 4
20.2 40/7C
C C
2 H2)N/R2 (CH 2 )-N m R3
in which m is an integer varying from 1 to 4 inclusive;
R 2 and R 3 are either similar or dissimilar and are
either hydrogen, alkyl (preferably of from 1 to 6
carbon atoms), branched chain alkyl, alkenyl, alkynyl
(each preferably containing 1 to 6 carbon atoms)-and
A preferred group of such compounds includes
derivatives in which one or more of the hydrogens of
the benzene rings is replaced by substituents seectd
from the group consisting,of hydrogen, an alkyl group..
having up to 6 carbon atoms, an alkenyl group having up
to 6 carbon atoms, a perfluoroalkyl group having up to
4 carbon atoms, a phenyl or a substituted phenyl
radical, amino, an alkylamino group having up to 4
carbon atoms, a dialkylamino group having up to 4 carbon
atoms (halogen, particularly fluorine or chlorine),
hydroxyl, an alkoxyl group having up to 4 carbon atoms,
a perfluoroalkoxyl group having up to 4 carbon atoms,
mercapto, an alkylmercapto group having up to 4 carbon
atoms, a perfluoroalkylmercapto group having up to 4
3 448.564
20.2 4 070
carbon atoms. More than one of these substituents may be on each ring. These substituents are identified in the formula as X or X'.
An especially preferred group of compounds included within the scope of my invention is
represented by the formula:
CH22 2 R "3
in which R 2 and R 3 are either hydrogen, alkyl
(preferably of from 1 to 6 carbon atoms), alkenyl, alkynyl (each preferably of from 1 to 6 carbon atoms).
The dotted line in the formula represents either an additional carbon to
carbon single bond or 2 hydrogens attached to the
adjacent carbons.
Illustrative of the compounds included within the scope of the invention are 2-(phenylethynyl)- 2 4 benzylamine, -methoxyphenylethynyl)-benzylamine, 2-(4-tolylethynyl)-benzylamine, 2-(4-fluorophenyl-
ethynyl)-benzylamine, trans-2-styrylbenzylamine,
trans-2-(4-methoxystryl)-benzylamine, the corres-
ponding N--alkyl and the N,N-dialkyl derivatives thereof.
The compounds represented above, in either
their free base or salt form, possess useful pharma-
cological properties. In particular, they have been
4 48.564
24 0/7O found to possess antiarrhythmic activity. It has been found that the administration of compounds of the
present invention, depicted in the above formula, results
in the prevention of arrhythmia in animals under
conditions which ordinarily cause the development of
arrhythmia in the animal 100% of the time.
It has further been found that administration
of the compounds of the present inventionwill arrest
an existing arrhythmia in the animal being treated and
cause a resumption of normal cardiac rhythm. As anti- arrhythmic agents, these compounds may be administered
orally or parenterally. The formulations for admini-
stration may be prepared in conventional manner,
employing conventional pharmaceutical carriers and
excipients.
The non-toxic acid addition salts useful as
components in the compositions provided by the present
invention are salts formed by the reaction of an
equivalent amount of the amine compound of the above
formula and an acid which is pharmacologically
acceptable in the intended doses. Salts of the above
compound which are useful are salts of the amine with
hydrochloric acid, hydrobromic acid, sulfuric acid,
phosphoric acid, fumaric acid, acetic acid, propionic
acid, lactic acid, gluconic acid, maleic acid,
succinic acid, tartaric acid, and the like. Salts of
these acids with the amine base are useful as the
active component of the compositions in the method of
this invention.
448,564
20,2 4 Ono The daily doses are based on the total body
weight of the test animal and vary between about 1.00
and 100.00 mg./kg. for mature animals. Thus, a unit
dose based on four-times-a-day administration is
between 2.5 mg. and 250 mg. for a 10 kg. dog, and a
total daily dose for a 10 kg. dog would vary between
about 10 mg. and 1,000 mng. For larger animals, up to
100 kg. and above, proportional dosages are employed,
based on the weight of the animal. Suitable dosage
units provided for the administration of the composi-
tions used in the method of the invention are tablets,
capsules (which may be suitably formulated for either
immediate or sustained release), syrups, elixirs,
parenteral solutions, and the like. These dosage
forms preferably contain per unit one or more multiples
of the desired dosage unit in combination with the
pharmaceutically acceptable diluent or carrier
required for preparing the dosage unit.
The compounds represented by the above structural
formulas may be prepared as illustrated below:
448,5 64
2012 4 070 FLOW SHEET I
c c 'I
XC X- ha~l X S CH2)-CN -C m-1
X 1 X-
(CH 2 )-NH2 m m
IV. X' X -R
(CH 2 )-NHAlk CH _2N )m 2 m \R 3
V III
This step may include a homologation procedure
involving initial replacement of the hal substituent by
a carboxy substituent treatment of the chloro com- or treatment pound with lithium followed by carbonation of bromo compound with magnesium followed by carbonation),
followed by lithium aluminum hydride reduction of the
acid to the primary alcohol derivative S. conversion to (-CH2Br) the next higher homolog of
4 48.564
20.2 4 On7
wherein
R1 is hydrogen or lower alkyl (preferably of
from 1-5 carbon atoms); R2 and R 3 can be similar or dissimilar and are either
hydrogen, alkyl (preferably of from 1-6 carbon
atoms), aralkyl (preferably benzyl or
phenethyl), alkenyl, alkynyl and can b
X and X' are selected from the group consisting of
hydrogen, halogen (chlorine or fluorine),
alkyl (preferably of from 1-6 carbon atoms),
alkoxy (preferably of from 1-5 carbon
atoms), perfluoroalkyl trifluoro- methyl), alkylmercapto (preferably of from
1-6 carbon atoms);
m is an integer selected from the group
consisting of 1 to 4 inclusive; and
Alk is alkyl (preferably lower alkyl of from
1-6 carbon atoms).
In accordance with the process of my invention, a substituted or unsubstituted benzonitrile having a
phenylethynyl or phenylethenyl substituent is reduced
with an alkali metal hydride to form the corresponding
4 48,5 64
40 no benzylamine, 2-styryl benzylamine, (4'-methoxy- styryl)-benzylamine, 2-(4-fluorophenylethynyl)-
benzylamine, 2-(4-tolylethynyl)-benzylamine, 2-phenyl-
ethynyl benzylamine, 2-(4-methoxyphenylethynyl)-
benzylamine. The reduction is preferably effected by contacting the nitrile compound I in the structural
formulas illustrating the process of my invention in the presence of a suitable inert organic solvent, such
as tetrahydrofuran, ether or other solvents convention-
ally employed with lithium aluminum hydride. Preferably, this reduction is carried out in an ether. The tempera- ture at which the reduction is carried out is not
critical but-it is preferred to employ ambient tempera-
tures and a range of from 0 0 -50°C. is satisfactory.
The resulting benzylamine compound is readily recovered
employing conventional techniques.
In preparing higher homologs of the benzyl-
amine compound, the starting halo compound S is
converted using conventional reaction methods to the
next higher homolog in which the halogen substituent
has been replaced by a halomethylene substituent
(-CH 2Br). Thus, the aralkenyl (or alkynyl) aryl halide
is treated with lithium followed by carbonation or with
magnesium to form the Grignard reagent followed by
carbonation to form the desired aralkenyl or (alkynyl)
aryl carboxylic acid. The thus-obtained acid is then
reduced using lithium aluminum hydride to produce the
corresponding substituted benzyl alcohol which is
recovered in accordance with conventional procedures and
9 4 8,564
20,2 treated with thionyl chloride, phosphorus tribromide
or the like to form the corresponding benzyl halide
X -C C X
CH 2 Hal VI
wherein Hal is bromo or chloro. The thus-obtained
product is purified using conventional techniques and
subjected to treatment with potassium cyanide thereby
completing the conversion of the intermediate benzo-
nitrile to the next higher homolog, the phenyl-
ethenylphenylacetonitrile or phenylethynylphenyl-
acetonitrile. The corresponding N-(phenylethenyl or phenyl-
ethynylbenzyl)formamide (IV) or higher homologs thereof
in which R 1 is hydrogen is prepared by formylation of
the benzylamine compound (II) employing conventional
conditions and reagents such as formic acid or esters
thereof for this purpose. The resulting formamide
derivative can be recovered in conventional manner.
The N,N-dimethylamine (III), wherein R 2 and R 3 each
represent methyl, is readily prepared by the treatment of
the primary amine compound (II) with formaldehyde and
formic acid in accordance with the known Eschweiler-
Clarke modification of the Leuckart Reaction. Recovery
of the N,N-dimethylamine is accomplished in conventional
manner. 'The N-methylbenzylamine, represented by (V)
wherein Alk is methyl, may be prepared by either
reduction of the corresponding N (phenylethenyl or
phenylethynyl -benzyl)formamide (IV) or by monodealkylation
of the corresponding N,N-dimethylamine (III) wherein R 2 448,564
2 4 0/7C and R 3 each represent methyl. Reduction of the formamido- derivative (IV) is effected utilizing lithium aluminum
hydride under the conditions set forth above for carrying
out the reduction of the corresponding benzonitrile
Similarly, dealkylation of the N.N dimethylamine (III) can be effected in known manner such as by treatment
with cyanogen bromide followed by hydrolysis of the
intermediate cyanamide or by treatment with a haloformate
followed by hydrolysis of the resulting urethane inter-
mediate. In each instance, the desired compound can be
recovered employing conventional techniques.
The N-loweralkylamines and the N,N-dilower- alkylamines corresponding to compounds and (III), respectively, are likewise prepared from the corresponding
primary amine (II) by analogous reactions. Thus, the primary amine (II) is treated with a lower aliphatic
acid halide or anhydride of from 2-5 carbon atoms, e.g.,
acetyl chloride, acetic anhydride, propionyl chloride,
butyryl chloride or valeryl chloride to produce the N-
alkanoyl amide corresponding to (IV) as, for example,
the N-acetyl, N-propionyl, N-butyryl or N-valeryl amide.
The thus-obtained amide is reduced to the corresponding
N-loweralkyl benzylamine compound by reduction in the manner described for the corresponding benzonitrile
compound by reduction with lithium aluminum hydride. The secondary amine compounds produced in this manner are the N-loweralkyl derivatives of 2-(phenyl-
ethenyl or phenylethynyl)benzylamines as, for example, the
N-ethyl, N-propyl, N--butyl and the N-amyl derivatives.
The corresponding tertiary amines (III), the N,N-dilower-
alkyl derivatives, are prepared from the secondary amines
11 448.564
20,2 4 0no
by repeating the process employed in the preparation of the secondary amines. Thus, the amides of the secondary amines are prepared and reduced with lithium aluminum hydride to produce the corresponding tertiary amines as, for example, the corresponding N,N.-diethyl, N-ethyl--N. methyl, N,N-dipropyl, N,N-dibutyl and the N,N-diamyl derivatives of substituted and unsubstituted phenyl- ethenyl or phenylethynyl benzylamine.
In accordance with a further alternative process for the preparation of the primary, secondary,
and tertiary benzylamine products of my invention, a benzyl halide of formula (VI) hereinabove is converted
by reaction with ammonia or an amine to form the corres- ponding primary, secondary or tertiary amine (IIIA) as
indicated below
NH R3 1
X- C C -X l'Y- '=2C -X'
CH 2Hal CH2 R3 (VI) (IIIA)
4 48.564
20,2 40/70
The starting compounds of the process of my invention, that is the aralkenylbenzonitrile and the aralkynylbenzonitriles containing X and X' substituents in the aromatic rings, are either known compounds or may be prepared from the corresponding halo substituted compounds by replacement of the halogen with cyanide through reaction with cuprous cyanide in pyridine. Other similarly substituted compounds may be prepared in accordance with the following flow sheet:
13 4 48,564
2 40 n FLOW SHEET II
Q COOH CHO CH2COOH H C
x x+Kjj A yX y
y CN or Br
CH CH X B
y
H Br C C-C NaOEt ix x- S
y Y
D
In this instance, a known cyano or bromo
substituted benzaldehyde is condensed with a phenyl
acetic acid to produce, as a first intermediate
compound A, the appropriately substituted phenyl
cinnamic acid. This, in turn, is converted to the
desired stilbene intermediate B by decarboxylation.
The stilbene compound B in the trans form is then
brominated to produce Compound C, a stilbene
dibromide which is then dehydrohalogenated with
sodium methoxide in alcohol to produce the corres-
ponding alkynyl compound D having a bromo substituent
in the benzene ring. At any stage of the above-
the described process, the intermediates used in Y is preparation of the starting material wherein 4' 4 48,564
2 4 0/70 bromo can be converted to the corresponding compound
wherein y is cyano by treatment with cuprous cyanide.
Compounds B and C can exist in two isomeric forms,
the cis and trans isomers. These isomers have
different physical characteristics and therefore are
readily separable by conventional means as by crystal-
lization.
Example 1
2-(Phenylethynyl)-bromobenzene
To a solution of 9.2 g. (0.4 mole) of sodium
dissolved in 150 ml. of absolute ethanol is' added 15.0 g.
(0.036 mole) of trans-2-bromostilbene dibromide. The
mixture is stirred and is heated under reflux for one
hour. The bulk of the ethanol is removed by evaporation,
and the residue is diluted with one liter of water. The
oil that precipitates is extracted with ether. Evapora-
tion of the ether after drying over magnesium sulfate
gives 8.30 g. of clear oil, 2-(phenylethynyl) -bromo-
benzene, that is, 95% pure by GLC. Example 2
2-(Phenylethynyl)-benzylamine
A. 2-(phenylethynyl)-benzonitrile
A mixture of 8.30 g. (0.0323 mole) of
2-(phenylethynyl)-bromobenzene; 3.18 g. (0.036 mole)
of cuprous cyanide and 2.81 g. (0.036 mole) of
pyridine is stirred and is heated under reflux for
3 hours. The residue is partitioned between ether
and 3N hydrochloric acid and then filtered. The ether
phase is separated and is washed with 3N hydrochloric
acid (3 x 100 water (2 x 200 ml.) and dried over 10 4 48,564
20,24 017 magnesium sulfate. Evaporation of the ether gives
a dark oil. Fractional distillation of this oil
gives 2-(phenylethynyl)-benzonitrile, 2.16 g.,
b.p. 127-129°C. (0.1 mm.).
When the above process is repeated using
trans-2-cyanostilbene dibromide as the starting
material, the product formed is 2-(phenylethynyl)- 0 benzonitrile, b.p. 127-129 C. (0.1 mm.).
B. 2-(Phenylethynyl)-benzylamine hydrochloride A solution of 0.69 g. (0.0182 mole) of
lithium aluminum hydride in 15 ml. of ether is
cooled in an ice bath. To this solution is added
dropwise over 30 minutes, a solution of 2.16 g.
(0.0165 mole) of 2-(phenylethynyl)-benzonitrile in ml. of ether. The mixture is stirred-for one
hour at 0°C. A solution of 5N sodium hydroxide is
added dropwise until a clear ether phase is obtained.
The ether is decanted, and the red gelatinous residue
that remains is extracted with five 50 ml. portions of
ether. The combined ether phases are dried over magnesium
sulfate. The magnesium sulfate is removed by
filtration and the ether filtrate containing
2-(phenylethynyl)-benzylamine is treated with gaseous
hydrogen chloride. The crystalline precipitate is
removed by filtration and is recrystallized from
isopropyl alcohol and ether to give 2-(phenylethynyl)- 0 benzylamine hydrochloride, m.p. 187-188 C.
Anal. Calcd. for C 1 5 113N*HC1: C, 73.92; H, 5.78;
Cl, 14.55. Found: C, 73.60; H, 5.73; Cl, 14.35.
4 48,564
4 0/70 Example 3 2-(4.-MethoxyDhenylethynyl)-benzylamine
A. Trans-2-cyano-4'-methoxystilbene dibromide
A mixture of o-cyanobenzaldehyde and 4-
methoxyphenylacetic acid in approximately equimolar
proportions is refluxed in a mixture of acetic
anhydride and triethyl amine for 1.5 hours. The reaction mixture is diluted with water and the
formed trans a-(4-methoxyphenyl)-2 cyano-cinnamic
acid is precipitated and filtered from the diluted
reaction mixture.
The trans a-(4-methoxyphenyl)-2 cyano-
cinnamic acid is added portion-wise over a period of
about 10 minutes to redistilled quinoline containing
a catalytic amount of copper-chromium oxide catalyst
at a temperature of 225-230°C. in the proportion of
approximately 1 g. of acid of to 2.5 ml. of quinoline.
When carbon dioxide evolution ceases the reaction
mixture is cooled, decanted from the catalyst,
distilled under reduced pressure and the distillate
poured into dilute aqueous hydrochloric and the formed
cis 2 cyano-4'*methoxystilbene recovered by extraction
into methylene chloride. The methylene chloride
extract of product is washed to remove acid and after
removal of the solvent by evaporation under reduced
pressure the product is further purified by
distillation.
The cis 2-cyano-4' -methoxystilbene is
isomerized to trans 2-cyano-4'-methoxystilbene by
heating with iodine in nitrobenzene. Removal of the
17 448,5 64
2 4 0/7 iodine and nitrobenzene gives the crystalline trans
stilbene derivative.
The dibromide of the trans-2-cyano-4-methoxy
stilbene is prepared by treatment with an equimolar
amount of bromine in carbon tetrachloride and
crystallizes readily from the reaction mixture.
B. 2-(4-Methoxyphenylethynyl)-benzylamine
The dibromide prepared in Part A of this
example is treated in accordance with the procedure
of Examples 1 and 2 to produce 2-(4-methoxyphenyl-
ethynyl)-benzylamine, m.p. 206.5-2080C. Example 4
2-(Z-Tolylethynyl)-benzylamine hydrochloride
The procedure of Example 3 is repeated using
as the starting material B-tolylacetic acid and
o-bromobenzaldehyde to produce trans-2--bromo-4'-
methylstilbene dibromide.
The resulting dibromide is treated with
sodium methoxide dissolved in ethanol in accordance
with the procedure described in Example 1 to produce
2-(2 -tolylethynyl)-bromobenzene.
The 2-(p-tolylethynyl)-bromobenzene is then
converted in accordance with the procedures set forth
in Example 2 to produce 2-(p-tolylethynyl)-benzylamine 0 hydrochloride, m.p. 205-207 C. Example
-Fluorophenylethynyl)-benzylamine hydrochloride
The procedure of Example 3 is repeated using
as starting materials approximately equimolar portions
of p-fluorophenylacetic acid and o-cyanobenzaldehyde n 44 8,5 64
20,2 4 no to produce 2-(-fluorophenylethynyl)-benzylamine 0 hydrochloride, m.p. 172-174 C. Example 6
Trans-2-styrylbenzylamine hydrochloride
To a solution of 0.86 g. (0.023 mole) of
lithium aluminum hydride in 30 ml. of ether is
added dropwise over 40 minutes a solution of 2.83 g.
(0.0138 mole) of trans-2-cyanostilbene in 70 ml. of
ether. The mixture is stirred for 1.5 hours at
room temperature and under reflux for one hour.
Water (10 ml.) is added dropwise until a thick
paste separates and a clear ether phase is obtained.
The ether is decanted and the solid residue is washed
with ether. The combined ether phases are placed in
a separatory funnel and shaken with 3N hydrochloric acid. A voluminous white crystalline precipitate
forms. This precipitate isremoved by filtration,
washed with ether and water, and is recrystallized
from water to give trans-2-styrylbenzylamine 0 hydrochloride 0.25 H 20, m.p. 213-214 C. Anal. Calcd. for C 1 5 H 1 5NHC1'0.25 H 20: C, 71.99;
H, 6.24; Cl, 14.17. Found: C, 71.94; H, 6.36;
Cl, 14.18; H 2 0, 0.22 mole. Example 7
Trans-2-(4'-methoxystyryl)-benzylamine hydrochloride
The procedure of Example 6 is repeated
utilizing as the starting material the intermediate
trans-2-cyano-4'--methoxystilbene prepared in
accordance with the procedures of Example 3A herein--
above to produce trans-2-(4'-methoxystyryl)--benzyl- 0 amine hydrochloride, m.p. 204-205 C.
19 4 48,564

Claims (1)

  1. 2 0,2 4 0/70
    The claims defining the invention are as follows:
    1. The process of preparing a compound of the formula
    C C
    X X (CH) N m R3 wherein X and X' are selected from the group consisting of hydrogen, halogen selected from the group consisting of chlorine and fluorine, alkyl, alkoxy, perfluoroalkyl, alkylmercapto, and the dotted line is optionally an additional bond or 2 hydrogens; m is an integer selected from the group of 1-4 inclusive; and R 2 and R3 are either hydrogen, alkyl, aralkyl, alkenyl, alkynyl.
    which comprises either treating a compound of the formula
    C rC
    (CII2 CN m-1 with a metal hydride reducing agent to form the corres- ponding aralkenyl or aralkynylaralkylamine compound of the formula
    4 4 8.5 4
    20,2 400
    C C
    (CH 2 2--NH m
    and if desired converting said aralkylamine to the
    corresponding N-alkyl or N,N-dialkylamine, or (B)
    treating a compound of the formula
    C=C
    (CH2 Br
    with ammonia or an amine.
    2. The process of preparing a compound of
    X X1 the formula
    C- C
    (CH2)-NH 2 m
    wherein X, X' and m are defined as in Claim 1, which
    comprises contacting the corresponding compound of
    the formula
    C C x X
    (CH2 )--CN with ametal hydride reducing agent.
    with a metal hydride reducing agent.
    4 48,5 64
    3. The process according to Claim 2 which
    comprises contacting.2-(phenylethynyl)--benzonitrile
    with lithium aluminum hydride to form 2-(phenyl-
    ethynyl)-benzylamine.
    4. The process according to Claim 2 which
    comprises contacting 2-(4-methoxyphenylethynyl)-
    benzonitrile with lithium aluminum hydride to form
    2-(4-methoxyphenylethynyl)-benzylamine.
    The process according to Claim 2 which
    comprises contacting 2-(4-tolylethynyl)-benzonitrile
    with lithium aluminum hydride to form 2-(4-tolyl-
    ethynyl)-benzylamine.
    6. The process according to Claim 2 which
    comprises contacting 2-(4-fluorophenylethynyl)-
    benzonitrile with lithium aluminum hydride to form 2-(4-fluorophenylethynyl)-benzylamine.
    7. The process according to Claim 2 which
    comprises contacting trans 2-cyano stilbene with
    lithium aluminum Lydride to form trans-2-styrylbenzyl-
    amine.
    8. The process according to Claim 2 which 4 comprises contacting trans-2-cyano- '-methoxystilbene 4 with lithium aluminum hydride to form trans-2-(
    methoxystyryl)-benzylamine. n 448,564
    20,2 9. The process of preparing a compound of
    the formula
    which comprises treating the corresponding compound of
    the formula
    C C
    (CH2 Hal m wherein Hal is halogen with a compound selected from
    the group consisting of ammonia, a primary amine and-
    a secondary amine.
    A compound represented by the formula
    wherein X, R2 R 3 and m are defined as in Claim 1.
    11. A compound in accordance with Claim
    represented by the formula
    23 448.564
    20,2400m 12. A compound in accordance with Claim
    represented by the formula H C C
    X (CH 2 X m R3
    13. A compound in accordance with Claim 11
    consisting of 2-(phenylethynyl)-benzylamine.
    14. A compound in accordance with Claim 11
    consisting of 2-(4-methoxyphenylethynyl)-benzylamine.
    A compound in accordance with Claim 11
    consisting of 2-(4-tolylethynyl)-benzylamine.
    16. A compound in accordance with Claim 11
    consisting of 2-(4-fluorophenylethynyl)-benzylamine.
    17. A compound in accordance with Claim 12
    consisting of trans-2-styrylbenzylamine.
    18. A compound in accordance with Claim 12
    consisting of trans-(4-methoxystyryl)-benzylamine.
    DATED this TWENTYEIGHTH day of AUGUST, 1970 MERCK CO., INC. Patent Attorneys for the Applicant SSPRUSON FERGUSON
    S 44 8,564
AU20240/70A 1969-09-29 1970-09-23 Preparation of styryl benzylamines and phenethynyl benzylamines Expired AU448564B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
USUS801,987 1969-09-29

Publications (2)

Publication Number Publication Date
AU2024070A AU2024070A (en) 1972-03-30
AU448564B2 true AU448564B2 (en) 1972-03-30

Family

ID=

Similar Documents

Publication Publication Date Title
CA979460A (en) Phenoxy-hydroxypropylamines and their preparation
CA946413A (en) Preparation of polyfluoroolifins
AU445948B2 (en) 9-fluoro-16-fluoromethyleneprednisolone-21-oenanthate and preparation thereof
AU2024070A (en) Preparation of styryl benzylamines and phenethynyl benzylamines
CA948631A (en) Preparation of n-trityl-imidazoles and n-trityl-triazoles
CA892576A (en) Aminolignosulfonates and preparation thereof
CA818518A (en) Preparation of pyrazinoylguanidines and pyrazinamidoguanidines
CA818515A (en) Preparation of pyrazinoylguanidines and pyrazinamidoguanidines
CA818514A (en) Preparation of pyrazinoylguanidines and pyrazinamidoguanidines
CA827194A (en) Preparation of propynylsodium and propynyllithium
CA811199A (en) Preparation of methyladamantane and dimethyladamantanes
CA818513A (en) Preparation of pyrazinoylguanidines and pyrazinamidoguanidines
CA819758A (en) Aminoarylsilanolates and siloxanols and their preparation
CA819760A (en) Phenoxyhalopropanols and preparation thereof
CA809669A (en) Indolomorphans and preparation thereof
CA803519A (en) Azabenzocycloalkane-n-carboxamidines and preparation thereof
CA827172A (en) Trialkylsilylphenyldisiloxanes and preparation
CA811733A (en) Thionophosphates and thionophosphonates and their preparation
CA806266A (en) Polyisoureaethers and their preparation
CA825174A (en) 5-acyloxyuracils and their preparation
CA950909A (en) Sulphonylamino-pyrimidines and their preparation
CA818500A (en) Preparation of 2-mercaptoinosine and derivatives thereof
AU440056B2 (en) 1-phenoxy-2-aminoalkanes and processes forthe preparation thereof
CA822157A (en) Preparation of 4a-lower-alkyl naphthalenones
CA818576A (en) Preparation of amine-ethers